Ipsen Regulated Information | Investor Relations

Regulated Information
Shareholders Meeting

Period

Filter by

Reset

Showing: 1 – 05 of 167 Regulated Information

Show

Sort

22 April 2026

$Download Ojemda® approved in the European Union as the first targeted therapy in relapsed or refractory pediatric low-grade glioma regardless of BRAF alteration$

Ojemda® approved in the European Union as the first targeted therapy in relapsed or refractory pediatric low-grade glioma regardless of BRAF alteration

03 April 2026

Ipsen announces that Beech Tree has obtained an exemption from the obligation to submit a public tender offer

01 April 2026

Ipsen announces the availability of its 2025 Universal Registration Document

13 March 2026

Ipsen – February 2026 – Monthly information relative to the total number of voting rights and shares composing the share capital

12 March 2026

Ipsen appoints Michelle C. Werner as EVP, President of North America

1 2 3 4 … 34